Form 4: Entrada Therapeutics Exec Sells Shares for Tax Obligations

Entrada Therapeutics' President of Research & Development, Natarajan Sethuraman, sold 1,760 shares to cover tax withholding obligations.

Summary

• Natarajan Sethuraman, President, Research & Development of Entrada Therapeutics, Inc. (TRDA), reported a transaction on September 2, 2025.
• The transaction involved the disposition of 1,760 shares of Common Stock.
• The shares were sold at a weighted average price of $5.4302 per share, with individual sales ranging from $5.36 to $5.58.
• The purpose of the sale was to cover tax withholding obligations related to the vesting of previously granted Restricted Stock Units (RSUs).
• Following this transaction, Sethuraman Natarajan beneficially owns 197,899 shares of Entrada Therapeutics Common Stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations related to RSU vesting, which is a neutral event from an investment sentiment perspective.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, specifically a non-discretionary sale to cover tax liabilities. Such transactions are common across all industries when executive compensation includes equity awards that vest.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related transaction and is unlikely to have a significant impact on shareholder sentiment or the company's valuation.
• Employees: The transaction reflects standard equity compensation practices for executives.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale by an insider to cover tax obligations upon RSU vesting. This is a routine event and does not indicate a change in the insider's view of the company's prospects, nor does it provide new information that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Entrada Therapeutics, TRDA, Form 4, Insider Trading, Stock Sale, Tax Withholding, RSU Vesting, Natarajan Sethuraman